Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)

Conditions

Metastatic Breast Cancer

Keywords

Metastatic breast cancer, Tumor biopsy, Phenotype and genotype characterization

Brief summary

The primary objective is to compare the phenotype and genotype of the primary tumor with those of its metastases in order to optimize the treatment of metastatic disease, in patients presenting with first metastatic progression of breast cancer.

Callens C, Driouch K, Boulai A, Tariq Z, Comte A, Berger F, Belin L, Bièche I, Servois V, Legoix P, Bernard V, Baulande S, Chemlali W, Bidard FC, Fourchotte V, Salomon AV, Brain E, Lidereau R, Bachelot T, Saghatchian M, Campone M, Giacchetti S, Zafrani BS, Cottu P.

2021-03-1517 citations

10.1186/s13073-021-00862-6

Systematic biopsy of the first metastatic event in breast cancer: Results from ESOPE—A prospective multicenter trial.

Aurélie Comte, Paul Cottu, Lisa Belin, Céline Callens, Vincent Servois et al. (14 authors)

Journal of Clinical Oncology2016-05-201 citations

10.1200/jco.2016.34.15_suppl.550

Abstract P2-05-06: Clinical utility of systematic biopsy of first metastatic event in breast cancer: Results from a prospective multicenter trial

Aurélie Comte, Brigitte Sigal‐Zafrani, Lisa Belin, Ivan Bièche, Céline Callens et al. (13 authors)

Cancer Research2016-02-151 citations

10.1158/1538-7445.sabcs15-p2-05-06

Abstract P6-03-05: Dual HER2 blockade of an activating driver <i>HER3</i> mutation: A proof of principle study in a metastatic breast cancer patient

François‐Clément Bidard, CK Ng, Ezgi Tulukcuoglu, Salvatore Piscuoglio, Stéphanie Descroix et al. (13 authors)

Cancer Research2015-05-01

10.1158/1538-7445.sabcs14-p6-03-05

Interventions

OTHERbiopsy or cytopuncture

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

To be eligible to participate in the study, patients must fulfill all of the following criteria: Female patients. Age ≥ 18 years. ECOG performance status ≤ 2. Metastatic breast carcinoma, either at diagnosis or at first metastatic relapse. Available FFPE +/- frozen primary tumor samples. Evaluable metastatic disease. Metastatic disease outside any previous radiotherapy field (e.g. sub-clavicular or internal mammary lymph nodes). Metastatic disease accessible to either percutaneous or surgical sampling. Signed written informed consent (approved by an Independent Ethics Committee and obtained prior to any study-specific screening procedure). Social and psychological welfare in concordance with compliance to the study.

Exclusion criteria

To be eligible to participate in the study, patients must fulfill none of the following criteria: Bilateral or multifocal breast cancer. Isolated local or contralateral relapse. Solitary bone and/or brain metastatic disease unless : Metastatic sites eligible for a therapeutic surgery. Metastatic sites sampled for diagnosis purpose. Past or current history of malignant neoplasms, except for curatively treated basal and squamous cell carcinoma of the skin. Carcinoma in situ of the cervix. Any coagulopathy contraindicating tumor biopsy. Presence of a contraindication to general anesthesia, if required.

Design outcomes

Primary

Measure	Time frame
To assess the phenotype ant genotype discrepancies regarding hormonal receptor, FISH status and proliferation between the primary tumor and the first metastatic progression.	2 years

Countries

France

Outcome results

None listed